Clinical Trials Directory

Trials / Completed

CompletedNCT04895059

Study of no Pharmacokinetic Interaction Between Rosuvastatin 20mg and Ezetimibe10mg, Fixed Dose vs Individual Components

Study of no Pharmacokinetic Interaction Between Rosuvastatin 20 mg and Ezetimibe 10 mg, Open Design, Randomized, Single Dose, 3x6, Crossove, Healthy Volunteers in Fasting, in Fixed Combination Against Individuals Components Managed

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
36 (actual)
Sponsor
Laboratorios Silanes S.A. de C.V. · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

Monocentric study of no pharmacokinetic interaction between rosuvastatin 20 mg and ezetimibe 10 mg. An open design, randomized, single dose with three periods, six sequences and crossed, in healthy volunteers with fasting conditions, managed in fixed dose combination (Sponsor Laboratorios Silanes S.A. de C.V.) versus individual components managed by separated (Crestor®, product of Astrazeneca, S.A. de C.V and Ezetrol®. product of Undra S.A. de C.V.)

Detailed description

To statistically compare the bioavailability of rosuvastatin 20 mg and ezetimibe 10 mg in a pharmacokinetic non-interference study, after single-dose oral administration of a product with the fixed combination of active ingredients with respect to the individual components administered separately in healthy volunteers fasting. In the same way, the safety of the presentations will be evaluated based on the registry of adverse events at the end of the three study periods. The classic 90% confidence intervals will be determined for the intra-individual ratios (test / reference) of the main parameters AUC0-t, AUC0-inf, Cmax for rosuvastatin and ezetimibe.

Conditions

Interventions

TypeNameDescription
DRUGRosuvastatin (20mg) /Ezetimibe (10mg) in fixed doseForm: Tablets Dosage: 20 mg Adminstration way: Oral
DRUGRosuvastatin 20mgPharmaceutical Form: Tablets Dosage: 20 mg Adminstration way: Oral
DRUGEzetimibe 10mgPharmaceutical Form: Tablets Dosage: 10 mg Adminstration way: Oral

Timeline

Start date
2017-04-30
Primary completion
2018-01-15
Completion
2018-01-22
First posted
2021-05-20
Last updated
2021-08-24

Locations

1 site across 1 country: Mexico

Source: ClinicalTrials.gov record NCT04895059. Inclusion in this directory is not an endorsement.